Chengdu, China

Xuehai Pang

This inventor holds 1 USPTO granted patent. Top assignee: Chengdu Easton Biopharmaceuticals Co., Ltd. Active years: 2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xuehai Pang. Retrieved from https://idiyas.com/inventor/xuehai-pang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Xuehai Pang: Innovator in Cancer Treatment

Introduction

Xuehai Pang is a prominent inventor based in Chengdu, China. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of innovative treatments for cancer. His work is characterized by a commitment to advancing medical science and improving patient outcomes.

Latest Patents

Xuehai Pang holds a patent for a new crystal form of lenvatinib mesylate and its preparation method. This invention is crucial as it provides a novel approach to creating a drug that can be used in the treatment of cancer. The patent highlights the importance of his research in developing effective therapies for this challenging disease.

Career Highlights

Pang is currently employed at Chengdu Easton Biopharmaceuticals Co., Ltd., where he continues to push the boundaries of pharmaceutical innovation. His work at the company has positioned him as a key player in the biopharmaceutical industry, contributing to the development of new and effective cancer treatments.

Collaborations

Throughout his career, Xuehai Pang has collaborated with talented professionals in his field, including Ying Wang and Haijian Huo. These collaborations have fostered a dynamic environment for research and innovation, leading to advancements in cancer treatment.

Conclusion

Xuehai Pang's contributions to the field of biopharmaceuticals, particularly through his patent on lenvatinib mesylate, underscore his role as an innovator in cancer treatment. His ongoing work at Chengdu Easton Biopharmaceuticals Co., Ltd. continues to inspire advancements in medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…